Of 89 patients receiving nightly subcutaneous deferoxamine for transfusion-dependent thalassemia major or Diamond-Blackfan anemia, 13 presented with visual loss or deafness of acute onset or both. Detailed ophthalmologic, audiologic, and evoked-potential studies uncovered abnormalities caused by neurotoxicity in 27 more. Four patients with visual loss had optic neuropathy, with a marked decrease in acuity, loss of color vision, and delayed visual evoked potentials. Five asymptomatic patients had changes in the pigment of the retinal epithelium. The hearing loss was characterized by a high-frequency sensorineural deficit, which necessitated hearing aids in six patients. When deferoxamine was stopped, recovery of vision was complete in 2 patients and partial in 2, and in 22 patients with abnormal audiograms, reversal of the hearing deficit was complete in 4 and partial in 1. An analysis of the clinical data showed that members of the affected group were younger, had lower serum ferritin values, and were self-administering higher doses of deferoxamine per kilogram of body weight. Significantly lower doses of deferoxamine were being taken by patients without abnormalities than by those with visual symptoms, abnormal audiograms, or prolonged evoked potentials (P less than 0.001, less than 0.006, and less than 0.04, respectively). The data implicate high-dose deferoxamine as a central factor in the pathogenesis of the neurotoxicity. We strongly recommend careful regulation of the deferoxamine dosage and serial audiovisual monitoring in all patients receiving the drug.
This article has been cited by other articles:
Henter, J.-I., Karlen, J.
(2007). Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood
109: 5157-5159
[Abstract][Full Text]
Li, C K, Chik, K W, Lam, C W K, To, K F, Yu, S C H, Lee, V, Shing, M M K, Cheung, A Y K, Yuen, P M P
(2002). Liver disease in transfusion dependent thalassaemia major. Arch. Dis. Child.
86: 344-347
[Abstract][Full Text]
Bergeron, R. J., Wiegand, J., Brittenham, G. M.
(2002). HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood
99: 3019-3026
[Abstract][Full Text]
Kushner, J. P., Porter, J. P., Olivieri, N. F.
(2001). Secondary Iron Overload. ASH Education Book
2001: 47-61
[Abstract][Full Text]
Bergeron, R. J., Wiegand, J., Brittenham, G. M.
(1999). HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood
93: 370-375
[Abstract][Full Text]
Bergeron, R. J., Wiegand, J., Brittenham, G. M.
(1998). HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood
91: 1446-1452
[Abstract][Full Text]
Yokel, R. A., Meurer, K. A., Hong, C. B., Dickey, K. M., Skinner, T. L., Fredenburg, A. M.
(1997). Short-Term Oral 3-Hydroxypyridin-4-one Dosing Increases Aluminum Excretion and Partially Reverses Aluminum-Induced Toxicity in the Rabbit Independent of Chelator Lipophilicity. Drug Metab. Dispos.
25: 182-190
[Abstract][Full Text]
Olivieri, N. F., Brittenham, G. M.
(1997). Iron-Chelating Therapy and the Treatment of Thalassemia. Blood
89: 739-761
[Full Text]
Lynch, S. G, Peters, K., LeVine, S. M
(1996). Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study. Mult Scler
2: 157-160
[Abstract]
Olivieri, N. F., Brittenham, G. M., Matsui, D., Berkovitch, M., Blendis, L. M., Cameron, R. G., McClelland, R. A., Liu, P. P., Templeton, D. M., Koren, G.
(1995). Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major. NEJM
332: 918-922
[Abstract][Full Text]
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., Cohen, A. R.
(1994). Survival in Medically Treated Patients with Homozygous {beta}-Thalassemia. NEJM
331: 574-578
[Abstract][Full Text]
Braatz, J. A.
(1994). Biocompatible Polyurethane-Based Hydrogel. J Biomater Appl
9: 71-96
Gómez, M., Domingo, J.L., del Castillo, D., Llobet, J.M., Corbella, J.
(1994). Comparative Aluminium Mobilizing Actions of Several Chelators in Aluminium-Loaded Uraemic Rats. Hum Exp Toxicol
13: 135-139
[Abstract]
Wong, V., Li, A., Lee, A.C.W.
(1993). Neurophysiologic Study of {beta}-Thalassemia Patients. J Child Neurol
8: 330-335
[Abstract]
Koo, W. W.K.
(1992). Review: Parenteral Nutrition-Related Bone Disease. JPEN J Parenter Enteral Nutr
16: 386-394
[Abstract]
VOLTI, S. L., GREGORIO, F. D., SCHILIROŇ, G.
(1990). Acute Changes in Renal Function Associated With Deferoxamine Therapy. Arch Pediatr Adolesc Med
144: 1069-1070
[Abstract]
deLemos, R. A., Roberts, R. J., Coalson, J. J., deLemos, J. A., Null, D. M. Jr, Gerstmann, D. R.
(1990). Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease. Arch Pediatr Adolesc Med
144: 915-919
[Abstract]
Freedman, M. H., Grisaru, D., Olivieri, N., MacLusky, I., Thorner, P. S.
(1990). Pulmonary Syndrome in Patients With Thalassemia Major Receiving Intravenous Deferoxamine Infusions. Arch Pediatr Adolesc Med
144: 565-569
[Abstract]
Koren, G., Bentur, Y., Strong, D., Harvey, E., Klein, J., Baumal, R., Spielberg, S. P., Freedman, M. H.
(1989). Acute Changes in Renal Function Associated With Deferoxamine Therapy. Arch Pediatr Adolesc Med
143: 1077-1080
[Abstract]
Fraser, C. L., Arieff, A. I.
(1988). Nervous System Complications in Uremia. ANN INTERN MED
109: 143-153
[Abstract]
Previous
